FDA approves Jascayd for idiopathic pulmonary fibrosis

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...

Orsini Selected as Specialty Pharmacy Partner for Boehringer Ingelheim's JASCAYD® (nerandomilast)

Orsini, a leader in rare disease pharmacy solutions, has been chosen by Boehringer Ingelheim as a specialty pharmacy partner ...
Medical Dialogues

Boehringer Ingelheim Jascayd tablets approved by USFDA for idiopathic pulmonary fibrosis

Ingelheim: Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration (FDA) for JASCAYD ...
Pulmonology Advisor

Jascayd Receives FDA Approval for Idiopathic Pulmonary Fibrosis

The Food and Drug Administration has approved Jascayd for the treatment of idiopathic pulmonary fibrosis in adult patients.
Medscape

FDA Gives Nod to Nerandomilast for Severe Lung Disease

Nerandomilast, marketed as Jascayd by its manufacturer Boehringer Ingelheim, is the first therapy approved in more than 10 ...
Healio

FDA approves nerandomilast for idiopathic pulmonary fibrosis

The FDA granted approval to nerandomilast, now Jascayd, for treating adults with idiopathic pulmonary fibrosis, marking the ...
Managed Healthcare Executive

FDA Approves a New Option for Idiopathic Pulmonary Fibrosis

Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both ...

Critical Mineral Resource at Falchani Exceeds 400,000 t Cesium (M+Ind) Within Existing Lithium Resource

American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | OTCQX:AMLIF | Frankfurt:5LA1) is pleased to highlight the globally significant cesium ...

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S.Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in ...
The Bakersfield Californian

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option ...

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capacity decline with JASCAYD versus placebo in adults ...